recombinant nematode anticoagulant protein c2
AssetAlso called rNAPc2, AB-201, ANPOCOGIN
Binds factor X or Xa to inhibit the tissue factor–factor VIIa complex and suppress coagulation.
- Stage
- Phase 1, no development reported
- Modality
- Protein or enzyme
- Target
- Not known
- 1
- Indication
- 7
- Trials
- 1
- Developer
Trial NCT00443573 suspended on May 7, 2008: Company suspended development of product. No trial still running and no development reported since. clinicaltrials.gov
Indications
1Colon cancer
Phase 1, Suspended, NCT00443573, clinicaltrials.gov, Nov 10, 2026
In the full profile
- Target and mechanism1
- Owner and partners1
- Trials7
- Evidence for its targets1
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.